Solventum (SOLV) Expected to Post Earnings on Thursday

Key Points

• Solventum is expected to report Q3 2026 results after the market closes on November 5. Analysts forecast earnings of $1.34 per share on $1.93 billion in revenue, while the company’s fiscal 2026 EPS guidance is $7.10–$7.20.
• In its latest quarter, Solventum reported $2.55 EPS and $2.21 billion in revenue, exceeding analyst estimates, with revenue rising 2.2% year over year.
• Analysts maintain a generally favorable view, with a consensus “Moderate Buy” rating and an $87.55 target price; shares recently traded at $81.75, down 1.5%.

Solventum (NYSE:SOLV - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $1.34 per share and revenue of $1.93 billion for the quarter. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Individuals may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Solventum (NYSE:SOLV - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period in the previous year, the firm earned $1.69 earnings per share. Solventum's revenue for the quarter was up 2.2% compared to the same quarter last year. On average, analysts expect Solventum to post $7.21 EPS for the current fiscal year and $7.23 EPS for the next fiscal year.

Solventum Trading Down 1.5%

Shares of NYSE SOLV opened at $81.75 on Thursday. Solventum has a 12 month low of $62.38 and a 12 month high of $94.16. The company has a market cap of $13.92 billion, a price-to-earnings ratio of 9.99, a P/E/G ratio of 1.31 and a beta of 0.63. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The business has a fifty day simple moving average of $88.36 and a 200-day simple moving average of $78.55.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wall Street Zen upgraded Solventum from a "hold" rating to a "buy" rating in a report on Saturday, September 12th. Canadian Imperial Bank of Commerce set a $35.00 target price on shares of Solventum in a report on Wednesday. KeyCorp lifted their target price on shares of Solventum from $93.00 to $102.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Piper Sandler lifted their target price on shares of Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Finally, BMO Capital Markets started coverage on shares of Solventum in a report on Wednesday, July 8th. They set a "market perform" rating and a $81.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $87.55.

About Solventum

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company's portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.